PERORAL FORMS OF CYTOSTATIC DRUGS IN THERAPY OF METASTATIC MAMMARY GLAND CANCER: ROLE IN CLINICAL PRACTICE
https://doi.org/10.21518/2079-701X-2016-10-74-83
Abstract
Modern therapeutic approaches allow achieving stable therapeutic effect, extension and maximum long-term preservation of the quality of life of metastatic mammary gland cancer patients. Currently there is no optimal consequence of cytostatic agents use. The advantage of using cytostatic peroral forms is related to easiness of their use in clinical practice, no necessity in venopuncture and reduction of need in hospitalization, as well as with the possibility of a more convenient therapy domiciliary. Due to active use of peroral forms of vinorelbine, fluoropyrimidines, methotrexate, cyclophosphamide, ethopozide, patients received a possibility to choose: to remain in the inpatient hospital or to undergo outpatient therapy domiciliary with minimum changes of the style of life.
About the Authors
G. M. TELETAEVA
FSBI Petrov Scientific and Research Institute of Oncology of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
T. Y. SEMIGLAZOVA
FSBI Petrov Scientific and Research Institute of Oncology of the Ministry of Health of Russia; State Budgetary Educational Institution of Higher Professional Education Mechnikov North-Western State Medical University of the Ministry of Health of Russia
Russian Federation
MD
Russian Federation
MD
А. S. ZHABINA
FSBI Petrov Scientific and Research Institute of Oncology of the Ministry of Health of Russia; State Budgetary Healthcare Establishment Saint-Petersburg Clinical Scientific and Practical Center of Specialized Medical Aid Types (Oncologic)
Russian Federation
Russian Federation
D. H. LATIPOVA
FSBI Petrov Scientific and Research Institute of Oncology of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
V. V. KLIMENKO
FSBI Petrov Scientific and Research Institute of Oncology of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
Z. S. KOTOVA
FSBI Petrov Scientific and Research Institute of Oncology of the Ministry of Health of Russia
Russian Federation
Russian Federation
A. I. SEMENOVA
FSBI Petrov Scientific and Research Institute of Oncology of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
S. A. PROTSENKO
FSBI Petrov Scientific and Research Institute of Oncology of the Ministry of Health of Russia
Russian Federation
MD
Russian Federation
MD
V. V. SEMIGLAZOV
FSBI Petrov Scientific and Research Institute of Oncology of the Ministry of Health of Russia; State Budgetary Educational Institution of Higher Professional Education Pavlov Saint-Petersburg State Medical University of the Ministry of Health of Russia
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
References
1. Семиглазов В.Ф., Палтуев Р.М., Семиглазова Т.Ю. и др. Опухоли репродуктивной системы. М.: Рекламно-издательская группа МегаПро, 2013./ Semiglazov V.F., Paltuev R.M., Semi glazova T.Y. et al. Tumors of reproductive system. M.: Advertising and Publishing Group MegaPro, 2013.
2. Переводчикова Н.И., Портной С.М., Стенина М.Б. Лекарственная терапия рака молочной железы. М.: Издательство Практика, 2014./ Perevodchikova N.I., Portnoy S.M., Stenina M.B. Drug therapy of mammary gland cancer. M.: Pulishing House Praktika, 2014.
3. Cardoso F et al. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2015, 22: vi25-vi30.
4. Ионова Т.И., Новик А.А., Сухонос Ю.А. Понятие качества жизни больных онкологического профиля. Онкология, 2000, 2 (1–2): 25-8./ Ionova T.I., Novik A.A., Sukhonos Y.A. Notion of quality of life of oncologic profile patients. Onkologia, 2000, 2 (1—2); 25-8.
5. Семиглазова Т.Ю., Семиглазов В.В., Филатова Л.В. и др. Качество жизни – важный критерий эффективности таргетной терапии метастатического поражения скелета при раке молочной железы. Опухоли женской репродуктивной системы, 2013, 1-2: 17- 22./ Semiglazova T.Y., Semiglazov V.V., Filatova L.V. et al. Quality of life is an important criteria of effectiveness of metastatic skeleton lesion at mammary gland cancer. Opukholi zhenskoy reproduktivnoy systemy, 2013, 1-2: 17-22.
6. Семиглазова Т.Ю., Жабина А.С., Осипов М.А. и др. Качество жизни – принципиальный критерий эффективности таргетной терапии метастатического HER2-положительного рака молочной железы. Современная онкология, 2015, 17 (1): 19-24./Semiglazova T.Y., Zhabina A.S., Osipov M.A. et al. Quality of life – principal criterion of effectiveness of target therapy of metastatic HER2-positive mammary gland cancer. Sovremennaya Onkologia, 2015, 17 (1): 19-24.
7. Телетаева Г.М. Основные принципы системной терапии при люминальном раке молочной железы (предоперационная, адьювантная и паллиативная). Практическая онкология, 2010, 11(4): 228-238./Teletaeva G.M. Major principles of systemic treatment at luminal mammary gland cancer (pre-operation, adjuvant and palliative). Prakticheskaya onkologia, 2010, 11 (4): 228-238.
8. Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2 negative (or unknown) advanced breast cancer: AmericanSociety of Clinical Oncology Clinical Practice Guideline. J Clin Oncol, 2014, 32: 3307-29.
9. Семиглазова Т.Ю., Гершанович М.Л. Пероральные фторпиримидины в химиотерапии злокачественных опухолей. Вопр онкологии, 2001, 47(4): 388- 94./Semiglazova T.Y., Gershanovich M.L. Peroral fluoropyrimidines in chemical therapy of malignant tumours. Vopr onkologii, 2001, 47 (4): 388-394.
10. Семиглазова Т.Ю., Гершанович М.Л. Кселода (капецитабин) в лечении диссеминированного рака молочной железы после исчерпанного эффекта антрациклинов и таксанов. Вопр. онкологии, 2001, 47(3): 298-302./Semiglazova T.Y., Gershanovich M.L. Xeloda (capecitabine) in therapy of disseminated mammary gland cancer after the exhausted effect of antracyclines and taxanes. Vopr onkologii, 2001, 47 (3): 298- 302.
11. Semiglazova T, Gershanovich M. The efficacy of Capecitabine (Xeloda) in Antracyclin- refractory and Antracyclin and Docetaxel-refractory metastatic breast cancer (MBC). Proc Am Soc Clin Oncol, 2002, 21: abstract 2061. P. 164.
12. Манзюк Л.В., Артамонова Е.В., Сатирова Е.Ф. Оригинальная комбинация Фторафур + Винорельбин в лечении рака молочной железы: первые результаты. Современная онкология, 2010, 1(12): 56-59./Manzyuk L.V., Artamonova E.V., Satirova E.F. Original combination Phthorafurum + Vinorelvine in therapy of mammary gland cancer: first results. Sovremennaya Onkologia, 2010, 1 (12): 56-59.
13. Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, et al; American Society of Clinical Oncology. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, 2014, 32: 2078-99.
14. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclindependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first- line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol, 2015, 16: 25-35.
15. Baselga J, Campone M, Piccart M et al. Everolimus in Postmenopausal Hormone- Receptor–Positive Advanced Breast Cancer. N Engl J Med, 2012, 366(6 Suppl): 520.
16. Seah DS, Luis IV, Macrae E, Sohl J, Litsas G, Winer EP, et al. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Natl Compr Canc Netw, 2014, 12: 71-80.
17. Dufresne A, Pivot X, Tournigand C, Facchini T, Alweeg T, Chaigneau L, et al. Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res Treat, 2008, 107: 275-9.
18. Dear RF, McGeechan K, Jenkins MC, Barratt A, Tattersall MH, Wilcken N. Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev, 2013, 12: CD008792.
19. Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, et al; ESOMBC Task Force. International guidelines for management of metastatic breast cancer: Combination vs sequential single-agent chemotherapy. J Natl Cancer Inst, 2009, 101: 1174- 1.
20. Tutt A, Ellis P, Kilburn L, Gilett C, Pinder S, Abraham K et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Presented at: 2014 San Antonio Breast Cancer Symposium; December 9-13, 2014. San Antonio, Texas. Abstract S3-01.
21. Gennari A, Stockler M, Puntoni M, Sormani M, Nanni O, Amadori D, et al. Duration of chemotherapy for metastatic breast cancer: A systematic review and metaanalysis of randomized clinical trials. J Clin Oncol, 2011, 29: 2144-9.
22. Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet, 2011, 377: 914-23.
23. Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, et al. Phase III open-label andomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and taxane. J Clin Oncol, 2015, 33: 594-601.
24. Семиглазова Т.Ю., Филатова Л.В., Гершанович М.Л. Комбинированная химиотерапия гемцитабином (Гемзаром) и цисплатином при диссеминированном раке молочной железы, прогрессирующем после лечения антрациклинами, доцетакселом и капецитабином. Вопросы онкологии, 2005, 51(1): 66-70./Semiglazova T.Y., Filatova L.V. Gershanovich M.L. Combined chemical therapy by gemcitabine (Gemzar) and cisplatin at disseminated mammary gland cancer progressing after therapy by anthracyclines, docetaxel and capecytabine. Voprosy Onkologii, 2005, 51 (1): 66-70.
25. Semiglazova T, Filatova L. Phase II study cisplatin plus gemcitabine (Gemzar) in antracycline, docetaxel and capecitabine-refractory metastatic breast cancer. Annals of Oncology. Abstract Book of the 29th ESMO Congress. Vienna, 2004. Vol.15. Suppl. 3. P. 43. 26. Семиглазова Т.Ю., Гершанович М.Л., Латипова Д.Х., Филатова Л.В., Чубенко В.А., Семиглазов В.В., Мацко Е.Д., Клименко В.В. Эффективность низких доз гемцитабина в комбинации с цисплатином в лечении диссеминированного рака молочной железы с прогрессированием после применения антрациклинов, таксанов и капецитабина. Фарматека, 2012, 8: 61-66./ Semiglazova T.Y., Gershanovich M.L., Latipova D.H., Filatova L.V., Chubenko V.A., Semiglazov V.V., Matsko E.D., Klimenko V.V. Effectiveness of low gencitabine dosages in combination with cisplatin in therapy of disseminated mammary gland cancer progressing after therapy by anthracyclines, docetaxel and capecytabine. Farmateka, 2012, 8: 61-66.
26. Malik PS, Raina V, Andre N. Metronomics as maintenance treatment in oncology: Time for chemo-switch. Front Oncol, 2014, 4: 76.
27. Gligorov J, Doval D, Bines J, Alba E, Cortes P, Pierga JY, et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): A randomised, open-label, phase 3 trial. Lancet Oncol, 2014, 15: 1351-60.
28. von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial. Lancet Oncol, 2014, 15: 1269-78.
29. Montagna E, Cancello G, Dellapasqua S, Munzone E, Colleoni M. Metronomic therapy and breast cancer: A systematic review. Cancer Treat Rev, 2014, 40: 942-50.
30. Schott S, Schneeweiss A, Reinhardt J, Bruckner T, Domschke C, Sohn C, et al. Acceptance of oral chemotherapy in breast cancer patients – a survey study. BMC Cancer, 2011, 11: 129.
31. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin, 2009, 59: 56-66.
32. Goodin S, Griffith N, Chen B, Chuk K, Daouphars M, Doreau C, et al. Safe handling of oral chemotherapeutic agents in clinical practice: Recommendations from an international pharmacy panel. J Oncol Pract, 2011, 7: 7-12.
33. Blum JL, Barrios CH, Feldman N, Verma S, McKenna EF, Lee LF, et al. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. Breast Cancer Res Treat, 2012, 136: 777-88.
34. Oostendorp LJ, Stalmeier PF, Donders AR, van der Graaf WT, Ottevanger PB. Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: A systematic review. Lancet Oncol, 2011, 12: 1053-61.
35. O’Shaughnessy JA, Kaufmann M, Siedentopf F, Dalivoust P, Debled M, Robert NJ, et al. Capecitabine monotherapy: Review of studies in first-line HER-2-negative metastatic breast cancer. Oncologist, 2012, 17: 476-84.
36. O’Shaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, et al. Randomized, openlabel, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol, 2001, 12: 1247-54.
37. Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, et al. apecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol, 2011, 29: 4498-504.
38. Kaufmann M, Maass N, Costa SD, Schneeweiss A, Loibl S, Sutterlin MW, et al; GBG-39 Trialists. First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial. Eur J Cancer, 2010, 46: 3184-91.
39. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2- negative, locally recurrent or metastatic breast cancer. J Clin Oncol, 2011, 29: 1252-60.
40. Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol, 2010, 28: 3256- 3.
41. Talbot DC, Moiseyenko V, Van Belle S, O’Reilly SM, Alba Conejo E, Ackland S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer, 2002, 86: 1367-72.
42. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O’Neill V, et al. RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety ofbevacizumab in combination with chemotherapy for secondline treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol, 2011, 29: 4286-93.
43. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol, 2005, 23: 792-9.
44. Reichardt P, Von Minckwitz G, Thuss-Patience PC, Jonat W, Kolbl H, Janicke F, et al. Multicenter phase II study of oral capecitabine (XelodaR) in patients with metastaticbreast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol, 2003, 14: 1227-33.
45. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, et al. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer, 2001, 92: 1759-68.
46. Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol, 2003, 21: 35-40.
47. Amadori D, Koralewski P, Tekiela A, Ruiz Simon A, Llombart A, Sommer H, et al. Efficacy and safety of navelbine oral (NBVO) in first line metastatic breast cancer. Eur J Cancer, 2001, 37(Suppl 6): Abstract 713.
48. Bartsch R, Pluschnig U, Wenzel C, Gampenrieder S, Altorjai G, Gnant M, et al. Oral vinorelbine in metastatic breast cancer: The Vienna experience. Ann Oncol, 2008, 19(Suppl 8): Abstract 160.
49. Blancas I, Morales S, Diaz N, Barnadas A, Gonzalvez ML, del Barco S, et al. Efficacy and safety of oral vinorelbine in first or second-line metastatic breast cancer. J Clin Oncol, 2010, 28(15S): Abstract 1090.
50. Mansour M, Haddad N. Phase II study of single agent oral vinorelbine as a first line chemotherapy for metastatic breast cancer patients previously treated with adjuvant anthracyclines and/or taxanes. Proc 21st International Congress on Anti-Cancer Treatment. 2010: Abstract 627.
51. Steger GG, Dominguez A, Switsers O, Dobrovolskaya N, Giotta F, Glogowska I, et al. Phase II study evaluating oral vinorelbine as a single- agent as first-line chemotherapy for metastatic breast cancer patients with bone metastases (NORBREAST-228 Trial): First efficacy results. Ann Oncol, 2014, 25(Suppl 4): Abstract 403P.
52. Tubiana-Mathieu N, Bougnoux P, Becquart D, Chan A, Conte PF, Majois F, et al. Alloralcombination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2- negative metastatic breast cancer: An International Phase II Trial. Br J Cancer, 2009, 101: 232-7.
53. Nole F, Crivellari D, Mattioli R, Pinotti G, Foa P, Verri E, et al. Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. ancer Chemother Pharmacol, 2009, 64: 673-80.
54. Campone M, Dobrovolskaya N, Tjulandin S, Chen SC, Fourie S, Mefti F, et al. A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines. Breast J, 2013, 19: 240-9.
55. Tawfik H, Rostom Y, Elghazaly H. All-oral combination of vinorelbine and capecitabine as firstline treatment in HER2/Neu-negative metastatic breast cancer. Cancer Chemother Pharmacol, 2013, 71: 913-9.
56. Finek J, Holubec L Jr, Svoboda T, Sefrhansova L, Pavlikova I, Votavova M, et al. A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer. Anticancer Res, 2009, 29: 667-70.
57. Delcambre C, Veyret C, Levy C, et al. A phase I/ II study of capecitabine combined with oral vinorelbine as first or second line therapy in locally advanced or metastatic breast cancer. Breast Cancer Res Treat, 2005, 94: S67 (Abstract 1081). 59. Jones A, O’Brien M, Sommer H, Nowara E, Welt A, Pienkowski T, et al. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Cancer Chemother Pharmacol, 2010, 65: 755-63.
58. Lorusso V, Spada M, Giampaglia M, Misino A, Calabrese R, Latorre A, et al; Gruppo Oncologico dell’Italia Meridionale. Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell’Italia Meridionale). Ann Oncol, 2006, 17: vii15-7.
59. Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, et al. rastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study. Cancer, 2007, 110: 965-72.
60. Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Jensen AB, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: The HERNATA study. J Clin Oncol, 2011, 29: 264-71.
61. Bergen E, Berghoff AS, Rudas M, Dubsky P, De Vries C, Sattlberger C, et al. Taxanes plus trastuzumab compared to oral vinorelbine plus trastuzumab in HER2- overexpressing metastatic breast cancer. Breast Care (Basel), 2014, 9: 344-8.
62. Andersson M, Lopez-Vega JM, Petit T, Zamagni C, Freudensprung U, Robb S, et al. Interim safety and efficacy of pertuzumab, trastuzumab and vinorelbine for first-line (1L) treatment of patients (pts) with HER2-positive locally advanced or metastatic breast cancer (MBC). Ann Oncol, 2014, 25(suppl 4): Abstract 361PD.
63. Andre N, Carre M, Pasquier E. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol, 2014, 11: 413-31.
64. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA, 2003, 100: 12917-22.
65. Kerbel RS, Guerin E, Francia G, Xu P, Lee CR, Ebos JM, et al. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis. Breast, 2013, 22(suppl 2): S57-S65.
66. Emmenegger U, Francia G, Chow A, Shaked Y, Kouri A, Man S, et al. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia, 2011, 13: 40-8.
67. Fedele P, Marino A, Orlando L, Schiavone P, Nacci A, Sponsiello F, et al. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. Eur J Cancer, 2012, 48: 24-9.
68. Martin M, Martinez N, Ramos M, Calvo L, Lluch A, Zamora P, et al. Standard versus ontinuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis. Oncologist, 2015, 20: 111-2.
69. Addeo R, Sgambato A, Cennamo G, Montella L, Faiola V, Abbruzzese A, et al. Lowdose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin Breast Cancer, 2010, 10: 301-6.
70. De Iuliis F, Salerno G, Taglieri L, Lanza R, Scarpa S. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer. Tumori, 2015, 101: 30-5.
71. Briasoulis E, Pappas P, Puozzo C, Tolis C, Fountzilas G, Dafni U, et al. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res, 2009, 15: 6454-61.
72. Rajdev L, Negassa A, Dai Q, Goldberg G, Miller K, Sparano JA. Phase I trial of metronomic oral vinorelbine in patients with advanced cancer. Cancer Chemother Pharmacol, 2011, 68: 1119-24.
73. De la Haba J, Cazzaniga M, Freyer G, Costa L, Petru E, Bartsch R, et al. Randomised phase II study evaluating, as first-line chemotherapy, single-agent oral vinorelbine administered with two different schedules in patients with hormone receptor positive, HER2-negative advanced breast cancer (TempoBreast-1 trial). Presented at: 2015 San Antonio Breast Cancer Symposium, December 8-12, 2015; San Antonio, Texas. Abstract OT3-02-04.
74. Colleoni M, Rocca A, Sandri MT, Zorzino L, MasciG, Nole F, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol, 2002, 13: 73-80.
75. Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic
76. breast cancer: antitumor activity and biological effects. Ann Oncol, 2006, 17: 232-8.
77. Gebbia V, Boussen H, Valerio MR. Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma. Anticancer Res, 2012, 32: 529-36.
78. Cazzaniga ME, Torri V, Villa F, Giuntini N, Riva F, Zeppellini A, et al. Efficacy and safety of the all-oral schedule of metronomic vinorelbine and capecitabine in locally advanced or metastatic breast cancer patients: The phase I-II VICTOR-1 study. Int J Breast Cancer, 2014, 2014: 769-90.
79. Cazzaniga ME. Metronomic chemotherapy (CHT) combination of vinorelbine (VRL) and capecitabine (CAPE) in HER2-advanced breast cancer (ABC) patients (pts) does not impair Global QoL. First results of the VICTOR-2 study. Presented at: ABC3, November 5-7, 2015: Lisbon, Portugal. Abstract PO64.
80. Montagna E, Lai A, Palazzo A, Bagnardi V, Cancello G, Iorfida M, et al. A phase II study of metronomic oral chemotherapy for metastatic breast cancer patients: Safety and efficacy results of vinorelbine, cyclophosphamide plus capecitabine (VEX) combination. Eur J Cancer, 2015, 51(Suppl 3): Abstract 1876.
Review
For citations:
TELETAEVA GM, SEMIGLAZOVA TY, ZHABINA АS, LATIPOVA DH, KLIMENKO VV, KOTOVA ZS, SEMENOVA AI, PROTSENKO SA, SEMIGLAZOV VV. PERORAL FORMS OF CYTOSTATIC DRUGS IN THERAPY OF METASTATIC MAMMARY GLAND CANCER: ROLE IN CLINICAL PRACTICE. Meditsinskiy sovet = Medical Council. 2016;(10):74-83. (In Russ.) https://doi.org/10.21518/2079-701X-2016-10-74-83
Views:
723
Email this article 